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Abstract: Plant-based diets rich in bioactive compounds such as polyphenols have been shown to
positively modulate the risk of cardiometabolic (CM) diseases. The inter-individual variability in the
response to these bioactives may affect the findings. This systematic review aimed to summarize
findings from existing randomized clinical trials (RCTs) evaluating the effect of hydroxycinnamic
acids (HCAs) on markers of CM health in humans. Literature searches were performed in PubMed
and the Web of Science. RCTs on acute and chronic supplementation of HCA-rich foods/extracts
on CM biomarkers were included. Forty-four RCTs (21 acute and 23 chronic) met inclusion criteria.
Comparisons were made between RCTs, including assessments based on population health status.
Of the 44 RCTs, only seven performed analyses on a factor exploring inter-individual response to
HCA consumption. Results demonstrated that health status is a potentially important effect modifier
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as RCTs with higher baseline cholesterol, blood pressure and glycaemia demonstrated greater overall
effectiveness, which was also found in studies where specific subgroup analyses were performed.
Thus, the effect of HCAs on CM risk factors may be greater in individuals at higher CM risk, although
future studies in these populations are needed, including those on other potential determinants of
inter-individual variability. PROSPERO, registration number CRD42016050790.
Keywords: polyphenols; caffeoylquinic acids; hydroxycinnamic acids; coffee; potato; artichoke;
cereals; dietary supplements; interindividual variability; cardiometabolic health
1. Introduction
Cardiometabolic (CM) diseases include cardiovascular diseases (CVD), diabetes and their related
risk factors, such as obesity, insulin resistance, impaired glucose tolerance, dyslipidemia, hypertension
and central adiposity. Recently, the Global Burden of Disease study stated that CM diseases are the
leading causes of death worldwide, mainly triggered by the rise in biomarkers of metabolic syndrome
(MetS), such as waist circumference (WC), fasting blood glucose, triglycerides (TG) and blood pressure
(BP) [1]. A diet rich in plant-based foods, such as fruit and vegetables, might decrease the risk of
CVD in all individuals [2–4]. Plant foods are generally rich in fiber, vitamins, minerals and other
bioactive compounds like glucosinolates, carotenoids and phenolic compounds. Phenolics are a family
of over 5000 compounds, which can be classified as flavonoids (i.e., flavonols, flavanones, flavones,
flavan-3-ols, isoflavones and anthocyanins) and nonflavonoids (including phenolic acids, lignans,
hydrolyzable tannins and stilbenes) [5,6]. Among nonflavonoids, phenolic acids are low molecular
weight compounds composed of at least one organic carboxylic acid bound to a phenol ring. Phenolic
acids can be in turn classified into hydroxybenzoic or hydroxycinnamic acids (HCAs), if deriving from
benzoic or cinnamic acid, respectively. Regarding HCAs, p-coumaric, ferulic and caffeic acids are the
most abundant in plant-based foods, but can also be bound to other organic acids, such as quinic
acid, by forming coumaroylquinic, feruloylquinic or caffeoylquinic acids (CQAs), mainly known as
chlorogenic acids (CGAs) [6–8].
HCAs are present in several food sources, including coffee, cereals, potatoes and artichokes
and, for this reason, they are generally ingested daily in high amounts with an estimated intake of
~200 mg/day in adults [9,10]. Once ingested, only a small part of HCAs are absorbed in the upper
gastrointestinal tract, while the majority reaches the colon unmodified, to be then subjected to extensive
catabolism by the gut microbiota [11]. These compounds and their metabolites, such as dihydrocaffeic
and dihydroferulic acids, have been associated with a wide range of biological activities, which may
contribute to the prevention of CM diseases [12]. For instance, HCA consumption has been shown
to exert anti-inflammatory activities, and play a role in glucose and lipid metabolism regulation in
in vivo animal and human studies [13]. However, despite the extensive literature available on this
topic, the evidence regarding the role of HCAs on CM health is not consistent [5,6,13,14]. This can be
partially due to the highly heterogeneous characteristics of human study participants recruited in the
different investigations [15].
An increasing number of studies investigating the health effects of plant food bioactives have
indeed shown that the response to the consumption of phenolic compounds may vary among different
individuals [16–19]. This inter-individual variability may be due to genetic and non-genetic factors,
such as age, sex, ethnicity and gut microbiota, and it may involve variations in human metabolism and
in the bioavailability of plant food bioactives [16,17]. These aspects may affect the biological response
on CM health outcomes and, as a result, some individuals may benefit more than others from the
health effects of these compounds. To better elucidate the impact of inter-individual variability on
the effects of phenolics on human health, some research groups have reviewed the current literature
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related to specific classes of phenolic compounds, namely the class of flavonoids, including flavanols
and flavonols, suggesting that these bioactives might be more effective in specific subgroups [18,19].
However, the inter-individual variability in the efficacy of the main dietary phenolic acids, namely
HCAs, which are consumed in abundance in coffee and cereals, has not been fully explored. Therefore,
the aim of this systematic review was to provide an overview of the randomized controlled trials
(RCTs) evaluating the effect of HCAs on markers of CM health, in order to increase the knowledge
about the impact of the inter-individual variability in the responsiveness to the consumption of this
class of phenolic compounds.
2. Materials and Methods
2.1. Search Strategy and Study Selection
This systematic review was conducted following the Cochrane Handbook for Systematic Reviews
of Interventions [20] and the Centre for Reviews and Dissemination’s guidance for reviews in health
care [21] and was reported in line with the PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) statement guidelines (Supplementary Table S1) [22]. The review protocol was
registered in the International Prospective Register of Systematic Reviews (PROSPERO, registration
number CRD42016050790) [23].
The systematic literature search was conducted using PubMed (http://www.ncbi.nlm.nih.gov/
pubmed) and the Web of Science (http://apps.webofknowledge.com) databases on December 2016
(updated December 2018), using the syntaxes reported in Supplementary Table S2. Electronic searches
were supplemented with manual searches of references from included studies and reviews on
similar topics. Studies were included in the present systematic review, based on the PICOS process
(Supplementary Table S3), if (i) they were RCTs investigating the effect of the consumption of HCA-rich
foods (artichoke, coffee, potato and cereal-based foods such as rye) or HCA extracts (i.e., containing
HCAs extracted from one of the above-mentioned HCA-rich foods) in humans, where this was
compared to a control, which was not high in HCAs; (ii) provided a quantitative characterization of the
HCA content and (iii) reported on one or more of the following CM markers: Body mass index (BMI),
WC, systolic and diastolic BP, TG, high-density lipoprotein cholesterol (HDL), low-density lipoprotein
cholesterol (LDL), flow-mediated dilation (FMD), blood glucose, blood insulin, glycated hemoglobin
(HbA1c), platelet aggregation or exercise capacity.
Exclusion criteria included (i) the presence of a co-intervention (e.g., physical activity) or other
confounding factors; and (ii) not reported in a European language. No restrictions for the characteristics
of study participants (e.g., age, sex and health condition) were applied.
2.2. Data Extraction
Two author-pairs independently assessed the studies for their inclusion. Disagreement between
authors was resolved through consultation with a third author (PM) who performed an independent
assessment to reach a consensus. Data were extracted from each identified study using a standardized
form and the following information was collected: Name of first author; year of publication; study
location; number of participants/controls; characteristics of intervention and placebo/control arms;
characteristics of test food (e.g., HCA content); potential factors (e.g., sex, pathophysiological status)
influencing the heterogeneity in the responses to the supplementation with HCA-rich food/extracts [24];
outcomes (BMI, WC, systolic and diastolic BP, TG, HDL, LDL, FMD, blood glucose, blood insulin and
HbA1c); main findings. Studies were also assessed for whether there were any assessments made to
explain inter-individual variability, including subgroup analyses (e.g., for age, pathophysiological
status, sex, dietary patterns or specific polymorphisms). For these studies, the above-mentioned data
were collected for each subgroup.
Data were then summarized by a qualitative assessment based on the results reported in individual
studies. For each outcome assessed, studies were grouped by those significant or not and baseline levels
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of the outcome were used to compare studies. For studies that explored inter-individual variability in
their own analyses, the results for each subgroup were assessed and summarized.
2.3. Risk of Bias
Risk of bias of the individual studies was assessed independently by two authors following the
Cochrane Risk of Bias Tool [20]. The following categories were assessed: 1. Sequence generation
and allocation sequence concealment (selection bias), 2. blinding of participants and personnel
(performance bias), 3. blinding of outcome assessment (detection bias), 4. incomplete outcome data
(attrition bias) and 5. selective outcome reporting (reporting bias). For each study, each category was
assessed as either “Low risk of bias”, “High risk of bias” or “Unclear risk of bias”.
3. Results
3.1. Study Selection
The study selection process is shown in Figure 1. A total of 811 records were identified through
the database search. After removing 185 duplicate articles, 626 studies were screened and 540 were
excluded based on the title or abstract. A total of 86 eligible records went under the full text screening
process, after which 41 records were excluded (Figure 1). Forty-five publications met eligibility criteria,
providing data on a total of 44 unique RCTs, which were assessed in the qualitative analysis. The
difference between the number of publications and the number of RCTs was due to the fact that three
publications were on the same RCT but reported on different CM risk factors and, in one case, one
publication reported results on two different RCTs.
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3.2. Characteristics and Risk of Bias of the Included Studies
The main characteristics of the included studies are reported in Tables 1 and 2. Out of the 45
included publications, 20 of them investigated the acute (i.e., single dose) effects of HCAs, which
provided data on 21 RCTs (Mills et al. [25] included two different RCTs in the same publication). The
remaining 25 publications investigated the chronic (2–16 weeks) effects of HCAs, which provided data
on 23 RCTs (Martínez-López et al. 2018, Sarriá et al. 2016 and Sarriá et al. 2018 [26–28] provided data
on different outcomes from the same RCT).
Most of the RCTs were performed in Japan (n = 11), followed by the United States of America and
the United Kingdom (n = 5), Australia and Iran (n = 4), Italy (n = 3) and Germany, Denmark, Norway,
Sweden, Finland, Greece, Thailand, Colombia, Mexico, Switzerland, Spain and Austria (n = 1).
For either acute or chronic studies, coffee was the most commonly investigated product, used as
the HCA-source in 30 RCTs either as a beverage (n = 27), coffee polyphenols (n = 2) or as a green coffee
extract (GCE; n = 1). Conversely, artichokes (n = 3), cereals (i.e., rye and wheat, n = 3) and potatoes
(n = 2) were the least used sources of HCA. Pure compounds were also tested (n = 6), including both 3-
and 5-CQA, ferulic acid or a mix of CGAs.
Risks of bias across the studies and within individual studies are shown in Supplementary
Figure S1 and Supplementary Figure S2, respectively.
Studies often lacked details useful to make a judgment, mainly no mention of whether there was
allocation concealment or blinding of outcome assessment, resulting in the majority of studies with
domains predominantly assessed as unclear risk of bias. Conversely, there was very little high risk of
bias observed where 0/21 acute studies and 4/23 chronic studies had only 1/5 domains (one study had
two domains) rated as high.
3.3. Impact of Hydroxycinnamic Acids on Cardiometabolic Markers
3.3.1. Acute Studies
Table 1 reports the main results obtained from the 21 acute studies evaluating the impact of
HCA-rich foods or dietary supplements (pure extracts) on CM health outcomes. As mentioned above,
coffee was the main HCA-rich source considered (n = 11), while only few studies were focused on
phenolic-rich extracts from coffee (n = 4), as well as on rye (n = 2), potatoes (n = 1) and pure CGAs
(n = 3). Total doses of CGAs ranged from ~3 mg [29] to 600 mg [30,31] for the phenolic-rich foods and
from 400 [32] to 900 mg [33] for pure compounds. The number of study participants ranged from
n = 9 [34] to n = 41 [35], while mean age ranged from 23 [25,29,36] to 59 years [33,37]. Overall, studies
were conducted on healthy individuals, except for two studies focused on overweight individuals [38]
and on individuals with borderline (systolic BP (SBP): 130–139 mmHg, or diastolic BP (DBP): 85–89
mmHg) or stage 1 hypertension (systolic BP: 140–159 mmHg, or diastolic BP: 90–99 mmHg) [39]
and one study on individuals who had self-reported gastrointestinal symptoms after eating cereal,
particularly rye [40].
Among the outcomes, markers of blood glucose metabolism (i.e., postprandial glucose and insulin)
were most often considered (n = 16), followed by BP (n = 8) and markers of endothelial function
(i.e., FMD, n = 8). There were no studies focused on platelet aggregation or exercise capacity. For acute
glucose metabolism, 16 studies reported a measure of postprandial glucose, 13 of which calculated an
incremental area under the curve (IAUC) [29–31,34–36,38,40–45], while three of them evaluated the
effect at various postprandial time points [37,39,46]. Of the 13 reporting an IAUC, only two reported a
significant reduction in IAUC for glucose after a HCA-rich intervention compared to a control [36,44],
whereas one study demonstrated an increase [43]. One of these two studies [36], conducted on 12
healthy young adults, found a significantly lower 2 h IAUC for glucose after consumption of 25 g
sucrose with coffee enriched with GCE and containing ~432 mg CGAs, compared to 25 g sucrose in
water. However, there was no effect when sucrose was consumed with normal or decaffeinated instant
coffee containing ~220 mg CGAs [36]. The second study [44] was conducted in 12 healthy young
Nutrients 2019, 11, 1805 6 of 30
adults who consumed one of three potato chips (from red, purple or white potatoes) containing up to
~360 mg CGAs and providing 50 g of available carbohydrates and compared to the consumption of 50 g
available carbohydrates from plain salted wheat crackers. The 2 h IAUC for glucose was significantly
lower after each of the potato chips compared to the cracker control. Nevertheless, it is possible that
the observed differences here may be confounded by the greater fat or fiber content of the potato chips
tested compared to the crackers. The one study that reported a significant increase in 2 h IAUC for
glucose was that by Robertson et al. [43], in which they only found the increasing effect on IAUC
glucose when caffeine was added to the test decaffeinated coffees in overweight men, using water as
the control drink. No effect on IAUC glucose was found between the test drinks and control when
the same amount of caffeine was added to each beverage. The study by Schubert et al. in 12 healthy
adults, however, did not find an effect of decaffeinated coffee vs. water in either case when consumed
without caffeine or when caffeine capsules were consumed [45]. However, Schubert et al. [45] used a
standard breakfast with the test beverages, which included pancakes, butter and jam as a means to
provide 48 g of carbohydrate as opposed to glucose load. Thus, the effects of caffeine on the glycemic
response may differ when consumed with carbohydrates, which may affect its metabolism [47].
Of the three studies that only reported differences in postprandial glucose at various time points,
one demonstrated a reduction at the peak glucose (30 min) after the ingestion of a coffee polyphenol
extract providing 355 mg CQAs consumed with a meal compared to when the meal was consumed
without the polyphenol extract in healthy men [46]. The other two studies found no differences
between test and control groups in postprandial glucose response. However, one of these [39] in 19
middle-aged adults with borderline hypertension found a significant increase in postprandial glucose
at 1 h and 2 h after the consumption of either the roasted coffee with CGAs or the coffee without CGAs.
This study differs from the other two in that the test and control beverages were consumed alone,
without a glucose load or meal as it was used in the other two studies, which may limit comparability
as well as applicability.
Twelve studies reported a measure of acute postprandial insulin, ten of which calculated an
IAUC [29–31,34,35,38,40–43] and two assessed the effect only at various postprandial time points [39,46].
Of the ten, one study reported a reduction in 3 h IAUC and one study an increase, while the others
found no significant effects. The one study that found the reduction in IAUC was conducted by
Rosen et al., which assessed five different varieties of rye made into breads and compared to a white
wheat bread in 14 healthy adults [29]. Interestingly, there were only two rye bread varieties, which
significantly reduced 3 h IAUC insulin compared to the white wheat control bread. These two breads
differed from the other three rye breads in that one (Rekrut) had the highest soluble fiber content and
the other (Amilo) had the highest insoluble fiber content, as well as higher levels of certain bioactives
including caffeic and sinapic acid. Dietary fiber content was related to the early (0–60 min) lower levels
of glucose and insulin and it has been previously demonstrated that breads made with endosperm rye,
which are rich in soluble fibers and bioactives, reduce glycaemia whereas wheat breads enriched in rye
do not [29]. Therefore, the bioprocessing may influence the metabolic effects of rye breads, as has been
previously reported [48]. On the other hand, the study that reported an increase in IAUC for insulin by
Rakvagg et al. [42], in 11 healthy young adults, only found a significant effect of the dark roast coffee
(66.6 mg CQA) vs. control (water), but not of the light roast coffee (~400 mg CQA), so the increasing
effect of the dark roast coffee may not be due to the CQA content but to some other confounding factors.
This study was also the only one to administer the interventions 30 min before the glucose load, which
may affect the interpretation and comparison of results. Of the two studies, which only reported the
effect of HCAs on insulin at various postprandial time points, no significant effects were found [39,46].
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Nine acute studies reported effects of HCA on BP [25,30–33,39,49], however only one demonstrated
a significant reduction and one a significant increase while the remaining seven studies did not find
significant effects. The study that demonstrated a reduction was performed in 23 healthy adults (mean
age 52 y) [32], found a significant reduction in SBP and DBP over 3 h after consumption of 400 mg
CGAs in 200 mL low nitrate water compared to plain water. It was not clear whether the control
water was matched for nitrate content and thus, since nitric oxide (which nitrate is a precursor to) is
a vasodilator, it may confound the effect on BP. The one study that found an increase was the one
performed by Ioakeimidis et al. [49] in 24 healthy adults (mean age 33 y), who showed a significant
increase in DBP and SBP over 2.5 h after consumption of a decaffeinated or caffeinated coffee (both
with 81 mg of 3-CQA and 156 mg of 5-CQA) or caffeine tablets compared to a control of hot water.
Interestingly, six of these nine studies assessing BP tested the effects of HCA when consumed alone
(without a meal or glucose load) [25,32,33,39,49]. Only one study was done in a population with
borderline or stage 1 hypertension (mean baseline SBP, 128 mmHg) [39], with the remaining in healthy
adults (all with mean baseline SBP < 125 mmHg, except one study with 130.5 mmHg). Therefore, the
applicability and generalizability of these results are limited.
Eight studies reported effects of HCAs on FMD with 50% (four studies) demonstrating a significant
increase in FMD compared to control [25,30,46], and two studies demonstrating a significant increase
in FMD within the HCA treatment [33,37], although not statistically significant compared to the control.
Interestingly, the two studies that did not demonstrate a significant effect only assessed FMD at 2 h
post-ingestion [32,39], whereas five of the six studies that found some significant effect assessed FMD
between 4–6 h post-ingestion, which may be of importance since most of the HCAs are not metabolized
until in the large intestine [5,6,11]. All studies were conducted in those who were healthy, other than
one in borderline or stage 1 hypertension [39], with mean BMI in the normal range (21.8–25.6 kg/m2)
and an average age of 45 y. Of the six studies that found some significant effects, four were conducted
solely in men, with the other two having 67% and 38% men, in contrast to the two studies without
significant effects, which had 58% and 17% men. Thus, these results may be indicative of a possible
effect in men, although more studies assessing this are needed, specifically including women, with
longer follow up for assessments (>2 h), and in higher risk populations.
In general, the acute studies demonstrated no effect of HCAs on glycaemia or BP, with some
potential effects on FMD. Limitations of the comparability of these studies include the wide variability
in terms of study design and methods of outcome assessment. Due to the vast majority of studies
being conducted in healthy participants and with HCA coming mainly from coffee consumed alone,
generalizability and applicability is also limited. From these studies it is unknown what the effects
may be in higher risk populations, including those with impaired glucose tolerance or diabetes, and
when HCAs are consumed as part of meals, which may be more common in real-world consumption.
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Table 1. Characteristics of the included acute intervention studies investigating the effect of HCA-rich foods on cardiometabolic markers.
Reference Study Participants StudyDesign Intervention Dose of HCAs Control/Placebo Main Findings
Beam et al. 2015 [41]
n = 10 male cyclists;
age 26 ± 5 y; BMI 24 ±
4.3 kg/m2
CO 75 g of dextrose with 10 mg/kg bw ofGC bean extract post-exercise
5 mg/kg bw CGA
(325–450 mg CGA)
75 g of dextrose with 5 mg/kg
bw caffeine
= blood glucose and insulin
2 h AUC, Matsuda Index
Boon et al. 2017 [37]
n = 12 (7M/5F); age
59.4 ± 6.4 y; BMI 24.7
± 3.3 kg/m2
CO
(1) 18 g of DC in 200 mL of hot water
taken after a 12-h fast; then again 2h
later plus 75 g glucose drink
(2) Note: Another treatment
included 18 g of ground caffeinated
coffee in 200 mL of hot water, taken
after a 12-h fast; then again 2 h later
plus 75 g glucose drink
(1) 287 mg CGAs (DC)
(2) 300 mg CGA
(caffeinated coffee)
200 mL of hot water, taken
after a 12-h fast; then again
2 h later plus 75 g
glucose drink
= 1 h FMD, 2 h glucose (at
any time point) and 1 h or 2 h
BP (based on a single reading)
↑FMD after caffeinated coffee
vs. DC or control
Ioakeimidis et al.
2018 [49]
n = 24 (16M/8F); age
32.7 ± 9.3 y; BMI 26.4
± 2.5 kg/m2 (habitual
consumers) and 26.4
± 2.5 kg/m2
(non-habitual
consumers)
CO (1) triple coffee espresso (75 mL)(2) triple DC espresso (75 mL)
81 mg of 3-CQA and
156 mg of 5-CQA
(1) 240 mg caffeine tablet
(2) placebo (hot water, 75 mL)
↑peripheral SBP, DBP after
DC, caffeinated coffee and
caffeine tablet compared to
placebo after 2.5 h
Iwai et al. 2013 [35]
n = 41 (22M/19F); age
34.8 ± 8.0 y; BMI 22.0
± 3.1 kg/m2
CO
2 pieces of Onigiri (200 g
carbohydrate) together with:
(1) 100 mg or
(2) 300 mg decaffeinated green coffee
beans extract in 200 mL water
39 and 118 g/day (39.2 g
CGA/100 g)
2 pieces of Onigiri (200 g
carbohydrate) together with
200 mL water
↓glucose after 300 mg
decaffeinated green coffee
beans extract compared to
control at 30 min
= insulin and glucose
2 h AUC
Johnston et al. 2003
[34]
n = 9 (4M/5F); age 26
± 3.2 y; BMI ≤
25 kg/m2
CO
25 g glucose in 400 mL of
(1) caffeinated or
(2) decaffeinated coffee
2.5 mmol CGA/L 25 g glucose in 400 mL water
= glucose, insulin at any
time point
↑0–30 min IAUC insulin
caffeinated coffee vs. DC
and control
Jokura et al. 2015 [46]
n = 19 M; age 38.1 ±
8.4 y; BMI 21.8 ±
2.2 kg/m2
CO
Meal (75 g carb, 28.5 g fat, 8 g
protein) with coffee
polyphenol extract
355 mg CQAs in 185 mL
Meal (75 g carb, 28.5 g fat, 8 g
protein) without coffee
polyphenol extract; matched
caffeine (54.9 mg)
↓peak postprandial blood
glucose at 30 min vs. control
↑ postprandial FMD at
60 min, 120 min, 180 min
over 4 h vs. control
= postprandial insulin
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Table 1. Cont.
Reference Study Participants StudyDesign Intervention Dose of HCAs Control/Placebo Main Findings
Kajikawa et al. 2019
[39]
n = 18 patients with
borderline or stage 1
hypertension
(12M/6F); age 56 ±
15 y; BMI 23.2 ±
3.1 kg/m2
CO Single intake of roasted coffee(beverage A)
412 mg CGAs
(beverage A)
Single intake of beverage C
(no CGAs)
= TG, glucose, insulin, FMD,
SBP vs. control
↑TG, glucose, insulin at 1 h
and 2 h within beverage A
and within control
↑FMD at 1 h and 2 h within
beverage A
Lappi et al. 2013 [40]
n = 15 (6M/9F); age 57
y; BMI 26 kg/m2;
healthy but
self-reported mild,
moderate or severe
gastrointestinal
symptoms
post-ingestion of
cereals,
particularly rye
CO
Meal including white wheat breads
fortified with bioprocessed rye bran
(WW + BRB) or with native rye bran
(WW + RB) providing 50 g of
available starch (meal also included
40 g cucumber, 20 g margarine, 14/15
participants also consumed black
coffee or tea)
- WW + BRB: 134.6 mg
total FA, 31.3 mg total
sinapic acid and 4.7 mg
coumaric acid
- WW + RB: 117.0 mg
total FA, 28.8 mg total
sinapic acid and 5.0 mg
total coumaric acid
Control meals including
wholegrain rye (R) bread
(74.0 mg FA + 17.1 mg SA +
2.9 mg CA) or white wheat
(WW) bread (6.6 mg FA + 1.7
mg SA + 0.2 mg CA)
providing 50 g of available
starch (meal also included 40
g cucumber, 20 g margarine,
14/15 participants also
consumed black coffee or tea)
= glucose
↓insulin incremental AUC for
R bread (control) compared
to others
Mills et al. 2017
[25]—Study 1
n = 15 M; age 26.3 ±
1.6 y; BMI 23.5 ±
0.5 kg/m2
CO LPC and HPC coffees 89 mg (LPC) and310 mg (HPC) CGA
Caffeine control: 110 mg
caffeine and 0 mg CGA in
hot water
↑FMD at 1 h and 5h for 450
mg and 900 mg CGA vs.
control
= SBP, DBP
Mills et al. 2017
[43]—Study 2
n = 24 M; age 23.8 ±
1.4 y; BMI 23.2 ±
1.4 kg/m2
CO
450 mg purified 5-CQA + 1 g
maltodextrin; 900 mg purified
5-CQA + 1 g maltodextrin
450 mg and
900 mg CGA
1 g maltodextrin (negative
control) and 200 mg
(−)-epicatechin + 1 g
maltodextrin
(positive control)
= FMD
↑FMD at 1 h within 450 mg
CGA
= SBP, DBP
Moser et al. 2018 [44]
n = 12 (6M/6F); range
age 19–33 y; BMI 23.2
± 0.7 kg/m2
CO
Potato chip product made from (1)
white, (2) purple or (3) red potatoes
providing 50 g of available
carbohydrates (~93 g potato chips)
Total CGAs ranging
from 13.4 ± 0.8 to 362.1
± 9.2 mg/100 g dw
Plain salted wheat crackers
providing 50 g of
available carbohydrates
↓mean 2 h glucose IAUC and
glucose at 20, 40 and 60 min
time points to each potato
chip vs. control
Mubarak et al. 2012
[32]
n = 23 (4M/19F); age
52.3 ± 10.6 y; BMI 25.6
± 4.7 kg/m2
CO 400 mg CGAs in 200 mL of lownitrate water 400 mg CGAs (3-CQA) Water
↓SBP, DBP (mean of 60, 90,
120 and 150 min)
= FMD at 120 min
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Ochiai et al. 2014 [31]
n = 14 M; age 36.2 ±
7.8 y; BMI 22.7 ±
1.8 kg/m2
CO 225 mL of a 75 g glucose-equivalenttest solution with coffee polyphenols 600 mg CQAs
225 mL of a 75 g
glucose-equivalent
test solution
= glucose, insulin, SBP
Ochiai et al. 2015 [30]
n = 13 M; age 44.9 ±
1.4 y; BMI 21.9 ±
0.6 kg/m2
CO
Coffee bean polyphenols beverage in
100 mL of water followed by a test
meal (14 g of protein, 30 g of fat and
58 g of carbohydrates)
600 mg CGAs
Placebo beverage with same
taste followed by a test meal
(14 g of protein, 30 g of fat
and 58 g of carbohydrates)
↓DBP at 1 h vs. placebo
↑FMD at 6 h vs. placebo
= glucose, insulin, TG, TC
Rakvaag et al. 2016
[42]
n = 11 (4M/7F); age
26.2 ± 0.6 y; BMI 23.2
± 0.4 kg/m2
CO
300 mL of either light (LIR) or dark
(DAR) roasted coffee 30 min before
75 g OGTT
- LIR: 399.6 ± 12.5 mg
CQA/serving
- DAR: 66.6 ± 1.2 CQA
mg/serving
300 mL of tap water 30 min
before 75 g OGTT
↑insulin 2 h IAUC DAR vs.
control
= glucose
↑glucose 60 min time point
DAR vs. control
↓ISI (Matsuda) DAR and LIR
vs. control
Robertson et al. 2015
[43]
n = 10 overweight M;
age 30.4 ± 14.2 y; BMI
27.8 ± 2.2 kg/m2
CO
(i) 2, 4 or 8 g instant DC in 400 mL
water with caffeine added in
proportion (total 100, 200 or 400 mg
caffeine) all with 50 g glucose
(ii) 2, 4 and 8 g DC with a standard
100 mg caffeine added to each
47, 94 and 188 mg
CQAs/drink
(i) 400 mL water with
50 g glucose
(ii) 400 mL water with a
standard 100 mg caffeine
(i) ↑2 h IAUC glucose for 2
and 4 g DC vs. control
(i) = 2 h IAUC insulin, ISI
(Matsuda)
(ii) = 2 h IAUC glucose, 2 h
IAUC insulin, ISI (Matsuda)
Rosen et al. 2011 [29]
n = 14 (7M/7F); age
23.6 ± 0.5 y; BMI 22.0
± 0.5 kg/m2
CO
A portion of one of five whole grain
rye test breads (differing in rye
varieties) providing 50 g of
available starch
FA ranging from 2.2 to
2.6 mg/serving; sinapic
acid ranging from 724
to 993 µg/serving
122.7 g of WW bread
providing 50 g of
available starch
↓3 h IAUC insulin for two
rye test breads (Amilo and
Rekrut) vs. WW
= 3 h IAUC glucose
Schubert et al. 2014
[45]
n = 12 (3M/9F); age
26.3 ± 6.3 y; BMI 22.7
± 2.2 kg/m2
(n = 10 in
glucose analysis)
CO
A standardized breakfast (pancakes,
butter, and jam: 48 g carbohydrate,
17 g fat, 15 g protein) at 0 min plus:
(i) 225 mL of DC + placebo capsules
at 0 and 120 min
(ii) 225 mL DC + caffeine capsules at
0 and 120 min
248.9 ± 11.3 mg CGAs
per serving
A standardized breakfast
(pancakes, butter and jam: 48
g carbohydrate, 17 g fat and
15 g protein) at 0 min plus:
(i) Placebo (250 mg
Metamucil) capsules and
225 mL water at 0 and
120 min
(ii) Caffeine capsules and
225 mL water at 0 and
120 min
= 4.5 h IAUC glucose
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Thom 2007 [36]
n = 12 (6M/6F); age
24.2 ± 3.2 y; BMI <
25.0 kg/m2
CO
(i) 25 g of sucrose and 10 g of coffee
made with GCE
(ii) 25 g of sucrose and 10 g of
normal instant coffee;
(iii) 25 g of sucrose and 10 g of DC
all in 400 mL water
(i) ~432 mg CGA
(ii + iii) ~220 mg CGA
25 g of sucrose in 400 mL of
water
↓2 h IAUC glucose AUC for
GCE vs. control only
Van Dijk et al. 2009
[38]
n = 15 overweight M;
age 39.9 ± 16.5 y; BMI
27.6 ± 2.2 kg/m2
CO
Either (i) 12 g DC
(ii) 1 g CGA
30 min before a 75 g oral glucose
(i) 264 mg CGA
(ii) 1 g CGA
1 g mannitol 30 min before a
75 g oral glucose
= 2 h IAUC glucose and
insulin
↓glucose and insulin at
15 min CGA vs. control
Ward et al. 2016 [33]
n = 16 (6M/10F); age
58.9 ± 8.2 y; BMI 24.7
± 3.3 kg/m2
CO
200 mL warm water with either 450
mg and 900 mg purified 5-CGA
2 h after a standardized breakfast (2
pieces of white bread with cheese,
tub of plain yoghurt and water)
450 and 900 mg CGA
200 mL warm water with
either 0 mg purified 5-CGA
(control group) or 200 mg
purified (−)-epicatechin
(positive control)
2 h after a standardized
breakfast (2 pieces of white
bread with cheese, tub of
plain yoghurt and water)
↑continuous FMD vs. control
= BP, peak FMD
Legend: AUC: Area under the curve; BMI: Body mass index; BP: Blood pressure; BRB: Bioprocessed rye bran; bw: Body weight; CGAs: Chlorogenic acids; CO: Cross-over design; DAR:
Dark roasted coffee; DBP: Diastolic blood pressure; DC: Decaffeinated coffee; dw: Dry weight; EDGCB: Decaffeinated green coffee beans extract; F: Females; FA: Ferulic acid; FMD: Flow
mediated dilation; GCE: Green coffee; HPC: High polyphenol coffee; IAUC: Incremental area under the curve; ISI: Insulin sensitivity index; LIR: Light roasted coffee; LPC: Low polyphenol
coffee; M: Males; OGTT: Oral glucose tolerance test; SBP: Systolic blood pressure; WW: Whole wheat; =: No statistically significant effect; ↑: Significant increase; ↓: Significant decrease.
Age and BMI are mean ± SD.
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3.3.2. Chronic Studies
The main findings associated with the 23 chronic studies investigating the effects of HCA-rich
foods on cardiometabolic markers are reported in Table 2. Similar to the acute studies, coffee was the
most commonly investigated HCA-rich food (n = 15), followed by artichokes (n = 3), wheat (n = 1)
and potatoes (n = 1), while extracts or pure compounds were the subjects of three studies. The HCA
dose was sometimes difficult to identify (e.g., in some cases expressed as mg/kg body weight) but it
generally ranged from 25 mg CGAs [50] up to 1200 mg CGAs/day [51]. The number of participants
ranged from 10 [52] to 183 [53] while mean age ranged from 23 [52] to 54 years [54]. Most study
participants were generally healthy (n = 11), and sometimes with pathophysiological conditions such
as mild hypertension or hypertension (n = 4), non-alcoholic fatty liver disease (NAFLD, n = 1), MetS
(n = 2), impaired glucose tolerance (IGT, n = 1), impaired fasting glucose (IFG, n = 1), hyperlipidemia
or hypercholesterolemia (n = 3). Three studies recruited solely individuals with overweight or obesity.
The duration of the studies ranged from two weeks [52] to four months [55], although most studies
(n = 17) were 4–8 weeks long.
Lipid profile components (n = 22), blood glucose (n = 14) and BP (n = 13) were the CM outcomes
most often considered. There were no studies assessing platelet aggregation or exercise capacity.
As already observed in acute studies, results from the different investigations were often contrasting.
Regarding blood lipids, 55% of the studies (12/22 studies) demonstrated a significant effect on at
least one measure of the lipid profile (i.e., decrease in TG, LDL-C and total-C and/or increase in
HDL-C) following HCA consumption [28,50,51,53,54,56–62]. Fifty percent of studies (9/18 studies) that
measured both LDL and TC demonstrated a significant reduction in both [28,50,51,54,58–62], aside
from one which found significance only for TC [60]. In comparing those nine studies reporting a
significant reduction to those that did not, those that did had a greater baseline LDL level (~3.34 mmol/L
vs. 2.91 mmol/L). Furthermore, those studies that did find a significant reduction were also slightly
more overweight (BMI ~28.9 kg/m2 vs. 26.4 kg/m2). The average of the mean ages in each study was
similar between these groups (~43 y) and the ratio of men to women in each study was ~37% in those
studies that found an effect compared to 49% in those that did not. However, only one study [54]
assessed the effect separately for men and women and found consistent effects between sexes, except
for a reduction in TG, which was only found for women.
Considering the source of the HCAs consumed, in the nine studies that found a significant
reduction in TC or LDL, seven used capsules of extracts rich in HCAs [51,54,58–62], one used instant
soup enriched in GCE [50] and one used 6 g/d of a soluble green/roasted coffee blend [28]. This
contrasts the nine studies that did not find a significant improvement on TC or LDL, in which six
studies used brewed or canned coffee [53,56,57,63–65], one used a beverage enriched in GCE [30], one
fruit juice enriched in GCE [66] and one GCE in capsules [67]. Interestingly, one of the studies that
used brewed coffee found an increase in TC, as well as an increase in HDL, after the consumption of
750 mL/d of moderate roasted coffee in 84 healthy subjects for 12 weeks [56]. The authors suggested
that this increase in TC may be the result of the diterpenes (i.e., cafestol and kahweol) in coffee [68],
which are present in unfiltered coffee. The food source of HCAs (interfering effects of other compounds
in unfiltered coffee) may have influenced the difference in results between these two groups of studies.
For markers related to glucose metabolism, ~30% of the studies demonstrated a significant effect
on fasting glucose (6/19 studies) [26,51,60,62,67,69] or HbA1c (2/7 studies) [54,62] following HCA
consumption. In comparing those six and two studies that found a significant reduction to those
that did not, those that did had a greater baseline glucose level (~6.00 mmol/L vs. 4.91 mmol/L and
6.55% vs. 5.9%, respectively). Furthermore, those studies that did find a significant reduction were
also performed on slightly more overweight individuals (BMI ~27.9 kg/m2 vs. 26.2 kg/m2). The
average of the mean ages in each study was similar between these groups (~41 y) and the ratio of
men to women at ~45%. Of the nine studies that reported results for insulin, none demonstrated
a significant reduction, with one that found a significant increase [56]. For homeostatic metabolic
assessment-insulin resistance (HOMA-IR), 57% (4/7 studies) found a significant reduction [54,60,62,67]
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and one study found a significant increase [56]. In comparing the four studies that found a significant
reduction in HOMA-IR to the two that found no effect, the mean baseline HOMA-IR level was higher
(4.03 vs. 2.19), with similar BMI (31.3 vs. 29.5 kg/m2), age (45 vs. 44 y) and ratio of men to women (35%
vs. 41%). Furthermore, those four studies all used HCAs consumed in the form of capsules (ranging
from 372 mg to 600 mg/d CGAs from GCE or artichoke) [54,60,62,67] whereas the other three studies
all assessed the effect of HCAs consumed in brewed coffee (ranging from 9 mg/d CGAs to 216 mg/d
CGAs). Interestingly, the one study of 84 healthy adults that found a significant increase in insulin and
HOMA-IR [56], had a much lower difference in CGA between the two coffees (difference of 9 mg/d
of CGAs) compared to the rest of the studies, and the authors noted that the concentration of CGAs
upon analyses demonstrate that they did not differ between the two coffees [70], thus the differences
in outcomes may be the result of other differences between the coffees (e.g., N-methylpyridinium
(NMP)). Additionally, one of the two studies that did not find an effect of HOMA-IR [57], conducted
in 116 overweight adults, also described a similar intervention of brewed coffees to compare which
differed in CGAs by 9 mg/d, thus may also not have had an adequate difference in CGAs in order to
assess effectiveness.
The beneficial effects predominating in higher risk groups are further supported if we look at
those studies that were done in higher risk groups. For instance, the consumption of HCA-rich foods
provided beneficial effects to study participants with impaired glucose metabolism, who are at a higher
risk of type 2 diabetes mellitus. In fact, the oral consumption of 1200 mg CGA by 30 study participants
with IGT for 12 weeks [51], or 600 mg artichoke extract by 55 participants with IFG for eight weeks [62],
significantly reduced fasting glucose (from 5.7 ± 0.4 to 5.5 ± 0.4 mmol/L) as well as other parameters
such as the insulinogenic index and the homeostatic metabolic assessment (HOMA) index (−11.7%),
compared to controls. Similarly, a positive effect on fasting blood glucose was observed in two other
investigations on individuals with NAFLD supplemented with 1 g GCE/day (500 mg CGA) for eight
weeks [60], as well as in individuals with MetS who consumed two decaffeinated GCE capsules (372 mg
CGA/day) for eight weeks [67]. Interestingly, contrasting results were observed in four trials with
healthy study participants [26,69,71,72]. A statistically significant amelioration of fasting blood glucose
(from 107.6 ± 3.0 to 99.0 ± 2.5 mg/dL) was evidenced when healthy individuals consumed 185 mL
of a test beverage with 329 mg CGA for four weeks [69] or green-roasted coffee blends providing
510 mg HCA/day for eight weeks [26]. On the contrary, Vitaglione et al. [71] failed to find any effect on
blood glucose following an eight-week consumption of wholegrain biscuits (70 g, ~130 mg HCAs as
sum of ferulic, sinapic and coumaric acids), similarly to Robertson and colleagues [72], who found no
differences after the consumption of four cups/day of instant coffee (44 mg CGAs/serving) for 12 weeks,
compared to non-coffee consumers.
Regarding BP, most studies (62%, 8/13 studies) demonstrated a significant effect on either SBP
or DBP resulting from the consumption of HCA-rich foods [28,50,53,64–67,73]. In comparing those
eight studies that found a significant reduction to those that did not, those that did had a greater
baseline SBP level (~138 mmHg vs. 118 mmHg). Those studies that did find a significant reduction
were performed on slightly less overweight subjects (BMI ~26.3 kg/m2 vs. 27.8 kg/m2) with similar
mean ages (~45 y) and ratio of men to women (~46 vs. 43%). No study completed subgroup analyses
by BP status or by sex.
With regard to measures of adiposity, 29% (5/17 studies) demonstrated a significant reduction
in BMI, body weight or waist circumference [51,53,61,62,67]. In comparing those studies that found
a significant reduction to those that did not, those that did had a greater baseline BMI (29.8 kg/m2
vs. 27.0 kg/m2) and greater baseline waist circumference (106.2 cm vs. 97.7 cm). Those studies that
did find a significant reduction had similar mean ages (~44 vs. 43 y, respectively) and lower ratio of
men to women (~30% vs. 54%). Interestingly the populations of those studies that found a reduction
included (n = 1) mild hypertension, (n = 1) obese, (n = 2) impaired glucose tolerance and (n = 1)
metabolic syndrome.
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Table 2. Characteristics of the considered chronic intervention studies investigating the effect of HCA-rich foods on cardiometabolic markers.
Reference Subjects StudyDesign Intervention Dose of HCAs Control/Placebo Main Findings
Agudelo-Ochoa et al.
2016 [63]
n = 75 (38M/37F); age 38.5 ±
9 y; BMI 24.1 ± 2.6 kg/m2;
overall healthy
P
400 mL coffee/d containing a
medium (MCCGA) or high
(HCCGA) CGA content for 8 weeks
MCCGA =
420 mg/400 mL;
HCCGA =
780 mg/400 mL (each
with ~193 mg/d
caffeine)
No consumption of coffee
or placebo
=TC, LDL, HDL, TG,
FMD, BP
Bumrungpert et al.
2018 [59]
n = 48 with hyperlipidemia
(6M/42 F); age 48.7 ± 7.6 y
(FA) and 45.9 ± 7.8 y
(placebo); BMI 25.9 ±
5.3 kg/m2 (FA) and 26.6 ±
6.2 kg/m2 (placebo)
P 2 capsules of FA/day for 6 weeks 1000 mg FA/day 2 placebo capsules/dayfor 6 weeks
↓TC, LDL, and TG ↑HDL
= SBP, DBP, glucose,
BMI, WC
compared to control
Haidari et al. 2017
[61]
64 obese F; age 36.1 (GCE)
and 35.7 y (placebo); BMI
26.4 ± 2.5 kg/m2 (GCE) and
26.4 ± 2.5 kg/m2 (placebo)
P One capsule of 400 mg GCE/day for8 weeks 180 mg CGA/capsule
One placebo capsule of
400 mg starch/day for
8 weeks
↓BMI, TC, LDL
= HDL, TG, glucose,
insulin
in the GCE group +
compared to control
Kempf et al. 2015 [57]
n = 116 overweight
(39M/77F); age 50.6 ± 11.8 y
(M-coffee) and 48.0 ± 12.7 y
(D-coffee); BMI 32.4 ±
4.4 kg/m2 (M-coffee) and 33.9
± 4.6 kg/m2 (D-coffee)
CO 4–5 servings/day of 7.5 g MRC in125 mL water for 3 months 19.31 ± 0.28 mg/L CGA
7.5 mg/L dark roast coffee
(10.01 ± 0.28 mg/L CGA;
1.20 ± 0.03 mg/L
N-methylpyridinium;
caffeine-matched) in
125 mL water for
3 months
↓SBP in control vs.
M-coffee
↑TG within control
↑HDL within M-coffee
= BMI, DBP, glucose,
insulin, HOMA-IR, TC,
LDL, HbA1c between
M-coffee and control
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Kozuma et al. 2005
[50]
n = 117 M with mild
hypertension
-Group 46 mg (n = 29): age 42.9 ±
8.2 y; BMI 25.2 ± 4.0 kg/m2
-Group 93 mg (n = 28): age 43.3 ±
8.3 y; BMI 24.4 ± 2.6 kg/m2
-Group 185 mg (n = 31): age 43.4
± 8.4 y; BMI 25.1 ± 3.6 kg/m2
-Placebo (n = 29): age 43.1 ± 9.1 y;
BMI 24.0 ± 3.1 kg/m2
P
Soy sauce-flavored instant cup soup
containing 46 mg, 93 mg, or 185 mg
of GCE, once a day for 28 days
25 mg, 50 mg, and
100 mg CGAs,
respectively
Soy sauce-flavored
instant cup soup
without GCE, once a
day for 28 days
↓SBP and DBP in all
group compared to
baseline, significant for
93 and 185 g groups
compared to placebo
↓TC, LDL within
185 mg group
= BMI, TG, HDL
Lecoultre et al. 2014
[52]
n = 10 M; age 23 ± 2 y; BMI 22.6
± 0.6 kg/m2; healthy CO
4 cups of (i) caffeinated coffee high in
CGA (C-HCA), (ii) DC high in CGA
(D-HCA), or (iii) DC regular in CGA
(D-RCA) daily for 14 days, with 4 g
fructose/kg day the last 6 days
-C-HCA: 9% CGAs
-D-HCA: 9% CGAs
-D-RCA: 3% CGAs
No coffee + 4 g
fructose/kg d (high
fructose only) in the last
6 days
= TG, glucose, insulin
↑TG after control
Martínez-López et al.
2018 [28] *
n = 52: n = 25 NC (10M/15F) and
n = 27 HC (10M/17F); age 26.6 ±
7.7 y (NC-F), 24.7 ± 5.8 y (NC-M),
33.3 ± 10.2 y (HC-F), 34.8 ± 9.2 y
(HC-M); BMI 21.9 ± 2.5 kg/m2
(NC-F), 24.2 ± 2.8 kg/m2 (NC-M),
21.4 ± 2.5 kg/m2 (HC-F), 24.9 ±
2.3 kg/m2 (HC-M)
CO 6 g/day of soluble green/roasted(35:65) coffee for 8 weeks
510.6 mg/day HCAs
(~344 mg/d CGA) +
~120 mg caffeine
Control beverage
(water or an isotonic
drink) for 8 weeks
↓TC, LDL, TG
=HDL
↓TC, LDL, TG in
HC only
= TC, LDL, TG in
NC only
Ochiai et al. 2004 [55]
n = 20 M; age 37.2 ± 1.6 y (test)
and 34.8 ± 2.3y (placebo); BMI
24.7 ± 1.6 kg/m2 (test) and 23.8 ±
0.6 kg/m2 (placebo); healthy
P 1 bottle of 125 mL test drinkcontaining GCE for 4 months
140 mg
CGA/serving (28%) 125 mL GCE-free drink
= SBP, DBP, TC, LDL,
HDL, TG,
glucose, insulin
Ochiai et al. 2009 [64]
n = 21 with mild hypertension
and vascular failure; range age
30–64 y; BMI 24.2 ± 0.9 kg/m2
(active group) and 24.2 ±
1.1 kg/m2 (placebo group)
P 1 can (184 mL) of active beverage(canned coffee) for 8 weeks
Active beverage: 300
mg CGA/serving
(reduced in HHQ)
1 can (184 mL) of
placebo beverage for 8
weeks (reduced in
HHQ and CGA;
caffeine-matched)
↓SBP
= DBP, BMI, glucose,
HbA1c, TG, LDL, HDL
= DBP, glucose, BMI,
FMD, TC, LDL,
HDL, TG
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Rezazadeh et al. 2018
[58]
68 patients with MetS (19M/49F);
age 38.9 ± 6.9 y; BMI 34.3 ±
4.3 kg/m2
P 1800 mg/day ALE as four tablets for12 weeks 4%–5% CGAs 4 placebo tablets/day
↓TG, TC, LDL within
ALE
=HDL
↓TG in ALE vs. control
Riedel et al. 2014 [56] n = 84 (46M/38F); age 25.6 ± 5.8 y;BMI 22.9 ± 1.9 kg/m2; healthy CO
750 mL (6 coffee pads at 7.5 g) of
MRC per day for 4 weeks 19.2 ± 0.3 mg/g CGA
750 mL of DRC (10.0 ±
0.3 mg/L CGA; 1.20 ±
0.0 mg/L
N-methylpyridinium;
caffeine-matched) per
day for 4 weeks
↑TC within MRC only
↑insulin, HOMA-IR
within MRC and vs.
DRC (control)↑HDL
within MRC and DRC,
but greater in DRC
(control)
=LDL, TG and glucose
Robertson et al. 2018
[72]
n = 27: n = 19 (10M/9F) in the
coffee group; range age 18–42;
BMI 23.4 ± 3.0 kg/m2; n = 8
(4M/4F) in the control group;
range age 19–41; BMI 22.9 ±
3.1 kg/m2; overall healthy
P Four cups/day instant coffee for12 weeks 43.6 mg CGAs/cup
No coffee/caffeine for
12 weeks
= fasting glucose,
insulin, TG, BMI
Rondanelli et al. 2013
[54]
n = 92 with mild
hypercholesterolemia (41M/51F);
age 54.2 ± 6.6 y (intervention)
and 53.8 ± 9.0 y (placebo); BMI
25.8 ± 3.9 kg/m2 (intervention)
and 24.8 ± 1.6 kg/m2 (placebo)
P Tablets of 250 mg ALE twice a dayfor 8 weeks >20% CQAs
Placebo tablets of 250
mg twice a day for 8
weeks
↑HDL within and
between groups
↓LDL and TC within
and between groups
= TG, glucose
Rondanelli et al. 2014
[62]
n = 55 overweight with IFG
(25M/30F) age 54.1 ± 9.8 y; BMI
30.7 ± 3.8 kg/m2
P 600 mg/day extract of Cs (30%–60%CQAs) tablets for 8 weeks
CQAs between 30%
and 60%
Placebo tablets for 8
weeks
↓BMI, glucose, HOMA,
TC, and LDL within Cs
and vs. control
↓HbA1c within Cs only
= insulin, HDL,
TG, WC
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Roshan et al. 2018 [67]
n = 43 with MetS (10M/33F); age
52.8 ± 9.8 y (CGE) and 52.0 ± 8.7
y (placebo); BMI 31.6 ± 3.6 kg/m2
(CGE) and 31.2 ± 4.9 kg/m2
(placebo)
P Two decaffeinated CGE capsules of400 mg/day for 8 weeks
372 mg CGA/day (186
mg/capsule)
Two placebo capsules
(starch)/day for 8 weeks
↓SBP, fasting glucose,
HOMA-IR, and WC
compared to placebo =
DBP, insulin, HbA1c,
BMI, TC, LDL, HDL,
TG
Sarriá et al. 2016 [27] *
n = 52 (20M/32F); age 29.8 ± 8.9 y
(M) and 29.4 ± 9.5 y (F); BMI 24.8
± 2.7 kg/m2 (M) and
21.7±2.5 kg/m2 (F)
CO 6 g/day of soluble green/roasted(35:65) coffee for 8 weeks
510.6 mg/day HCAs
(~344 mg/day CGA) +
~120 mg caffeine
Water or an isotonic
drink
↓glucose and
HOMA-IR ↑QUICKI
Sarriá et al. 2018 [26] *
n = 52: n = 25 NC (10M/15F) and
n = 27 HC (10M/17F); age 26.6 ±
7.7 y (NC-F), 24.7 ± 5.8 y (NC-M),
33.3 ± 10.2 y (HC-F), 34.8 ± 9.2 y
(HC-M); BMI 21.9 ± 2.5 kg/m2
(NC-F), 24.2 ± 2.8 kg/m2 (NC-M),
21.4 ± 2.5 kg/m2 (HC-F), 24.9 ±
2.3 kg/m2 (HC-M)
CO 6 g/day of soluble green/roasted(35:65) coffee for 8 weeks
510.6 mg/day HCAs
(~344 mg/day CGA) +
~120 mg caffeine
Water or an isotonic
drink
↓SBP, DBP ↓glucose,
HOMA-IR and TG
= HDL, insulin, waist
circumference
↓SBP, DBP, HOMA-IR,
TG in HC only
= HDL, glucose, insulin
in HC only
↓HOMA-IR in NC only
= SBP, DBP, TG, HDL,
glucose, insulin in NC
only
Shahmohammadi et
al. 2017 [60]
n = 44 (22M/22F) patients with
NAFLD; age 41.4 ± 7.7 y (GCE)
and 44.5 ± 5.2 y (placebo); BMI
31.3 ± 2.6 kg/m2 (GCE) and 31.5
± 2.2 kg/m2 (placebo)
P 1 g GCE/day for 8 weeks + advice on30 min/day exercise 500 mg CGAs/day
1 g placebo/day for 8
weeks + advice on 30
min/day exercise
↓TC, TG, fasting blood
glucose, HOMA-IR
= HDL, LDL, insulin,
WC, BMI
for GCE vs. control
Soga et al. 2013 [69]
n = 18 M; age 36.1 ± 7:4 y; BMI
21.9 ± 0.6 kg/m2 (CGA) and 22.0
± 0.5 kg/m2 (control); healthy
CO 185 mL of a test beverage with CGAsdaily for 4 weeks 329 mg CGAs/serving
185 mL of test beverage
without CGAs for 4
weeks;
caffeine-matched
↓glucose within CGA
= BMI
Vinson et al. 2012 [73]
n = 18 hypertensive (7M/11F);
age 54 ± 10 y; BMI 29.4 ±
6.4 kg/m2
CO 6–8 purple potatoes for 4 weeks 2.72 mg/g dw CGA;0.147 mg/g dw neoCGA No potatoes for 4 weeks
↓DBP within purple
potatoes
= SBP, glucose, HbA1c,
TC, HDL, TG
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Table 2. Cont.
Reference Subjects StudyDesign Intervention Dose of HCAs Control/Placebo Main Findings
Vitaglione et al. 2015
[71]
n = 68 overweight/obese
otherwise healthy (23M/45F); age
40 ± 2 y (WG) and 37 ± 2 y
(control); BMI 30.0 ± 0.5 kg/m2
(WG) and 29.5 ± 0.4 kg/m2
(control)
P 70 g/d (3 biscuits/d) of WG productsfor 8 weeks
96.7 mg FA/serving;
26.5 mg SA/serving; 9.4
mg CA/serving
1 package (33 g) of
crackers and 3 slices of
toasted bread for 8
weeks
= BMI, WC, glucose,
TC, HDL, TG
Watanabe et al. 2006
[66]
n = 28 with mild hypertension
(11M/17F); age 52 ± 11 y (CGA)
and 51 ± 8 y (placebo); BMI 23.8
± 3.3 kg/m2 (CGA) and 25.0 ±
3.5 kg/m2 (placebo)
P 125 mL/day fruit and vegetable juicemixed with GCE for 12 weeks 140 mg CGA/day
125 mL/day fruit and
vegetable juice for 12
weeks
↓SBP and DBP within
GCE
↓SBP GCE vs. control =
BMI, TC, LDL, HDL,
TG, glucose
Wedick et al. 2011 [65] n = 45 overweight (16M/29F); age40 y; BMI 29.5 kg/m2 P
5 cups (177 mL each) per day of (1)
DC or (2) caffeinated coffee for 8
weeks
(1) 216 mg/5 cups of DC
(2) 302 mg/5 cups for
caffeinated coffee
No coffee (i.e., water)
for 8 weeks
= BMI, WC, SBP, LDL,
HDL, TG, glucose,
insulin and HOMA-IR
↓DBP within DC
Yamaguchi et al. 2008
[53]
n = 183 with mild hypertension
(91M/92F); age 49.4 ± 10.1 y; BMI
25.4 ± 3.8 kg/m2
P
One can (184 mL)/day of zero-dose,
low-dose, middle-dose, high-dose
coffee for 4 weeks
82 mg (low-dose), 172
mg (middle-dose) and
299 mg (high-dose)
CGA/can
0 mg (zero-dose) coffee
(0 mg CGA)
↓SBP and DBP in low,
middle and high-dose
= LDL, TG
↑HDL and TC within
middle-dose
↓BW within middle and
high dose
Zuñiga et al. 2017 [51]
n = 30 (5M/25F) patients with
IGT; age 43 ± 11 y (CGA) and 45
± 9 y (placebo); BMI 32.6 ±
2.4 kg/m2 (CGA) and 32.1 ±
2.5 kg/m2 (placebo)
P Oral CGAs from GCE, three timesper day for 12 weeks 1200 mg CGAs/day
Oral placebo, three
times per day for 12
weeks
↓BMI, WC, TG, TC,
LDL, glucose
= SBP, DBP, HDL,
HbA1c within CGA
Legend: ALE: Artichoke leaf extract; AUC: Area under the curve; BMI: Body mass index; BP: Blood pressure; CA: Coumaric acid; CGA: Chlorogenic acid; CO: Cross-over design; Cs:
Cynara scolymus (artichoke); DC: Decaffeinated coffee; D-coffee: Dark roast coffee; DBP: Diastolic blood pressure; DRC: Dark roast blend coffee; dw: Dry weight; F: Females; FA: Ferulic acid;
FMD: Flow mediated dilation; GCE: Green coffee extract; HbA1c: Glycated hemoglobin; HC: Hypercholesterolemic; HCAs: Hydroxycinnamic acids; HDL: High density lipoprotein; HHQ:
Hydroxyhydroquinone; HOMA: Homeostatic model assessment; IFG: Impaired fasting glucose; IGT: Impaired glucose tolerance; IR: Insulin resistance; LDL: Low density lipoprotein; M:
Males; M-coffee: Medium roast coffee; MetS: Metabolic syndrome; MRC: Medium roast blend coffee; NAFLD: Non-alcoholic fatty liver disease; NC: Normocholesterolemic; P: Parallel
design; RCT: Randomized controlled trial; SA: Sinapic acid; SBP: Systolic blood pressure; TC: Total cholesterol; TG: Triglycerides; WC: Waist circumference; WG: Whole grain; =: No
statistically significant effect; ↑: Significant increase and ↓: Significant decrease. Age and BMI are mean ± SD. * These publications correspond to the same RCT.
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Overall, the results from each of the outcomes assessed in the chronic studies consistently
demonstrate there is a significant effect in those studies with participants with higher baseline levels of
each risk factor for CVD. Therefore, HCAs may be more effective in those at higher CVD risk.
3.3.3. Inter-Individual Variability
Only seven out of the 45 studies took into account one or more determinants that might explain
inter-individual variability, such as pathophysiological status (n = 4), sex (n = 2), dietary patterns
(n = 1) or specific polymorphisms (n = 1). The main findings of these studies are reported in Table 3.
It is worth noting that the role of polymorphisms was also considered by the study of Robertson
and colleagues, but the considered polymorphism (on the CYP1A2 gene) was related to the caffeine
metabolism and no insights in the metabolism or effect of HCAs were provided [72].
Among the studies investigating the putative role of pathophysiological status in the effects of
HCA-rich sources, two acute studies stratified results based on the glycemic response [35] or the
insulinogenic index (an index of pancreatic β-cell function) [46]. In the former, the consumption of
300 mg of decaffeinated green coffee beans (EDGCB) extract significantly lowered peak glycemic levels,
but not plasma glucose IAUC, after ingestion of a 200 g carbohydrate rich-meal, compared to water [35].
Interestingly, when results were analyzed on a sub-set of 18 study participants categorized as having
a high-glycemic response (i.e., those with the highest mean postprandial glucose level 30 min after
consumption of the loading diet/placebo food), plasma glucose 2 h IAUC was reduced following the
100 mg EDGCB beverage compared to control. Similarly, plasma glucose after 30 min was significantly
lower after the ingestion of both low (100 mg) and high (300 mg) intake of EDGCB beverages, compared
to controls. Jokura and colleagues [46] focused on the insulinogenic index and its potential role as a
determinant of the effect of HCA on postprandial hyperglycemia and vascular endothelial function. In
all study participants, the ingestion of a meal with a coffee phenolic extract (355 mg CQAs) beverage
significantly lowered the plasma glucose levels (p < 0.05) after 30 min and FMD response after 60 min
compared to the same meal without the coffee polyphenol extract. However, when study participants
were stratified by insulinogenic index, those with an index <0.88 had significantly lower postprandial
blood glucose concentration at 30 min (p < 0.01) compared to control, whereas there was no effect in
those with an index ≥0.88. Thus in those with lower β-cell function, and thus at greater risk of chronic
disease such as diabetes, there was an effect of HCA. With regards to the assessment of FMD, the
response seemed not to be influenced by the insulinogenic index, being significantly higher at 120 min
in both strata compared to control.
The role of background lipid status in determining the effect of HCA-rich foods on CM markers
was considered in one chronic study (two publications [26,28]) in which half of the recruited study
participants had hypercholesterolemia. In this study, daily consumption of green/roasted coffee blend
(344 mg CQAs and ~510 mg HCAs total, plus ~120 mg caffeine) for eight weeks resulted in decreased
the levels of several CVD risk factors including SBP, DBP, blood glucose, HOMA-IR, total-C, LDL-C
and TG. However, when the results were separated by hyperlipidemia status, SBP, DBP, total-C, LDL-C
and TG were significantly reduced after coffee consumption only in those with hyperlipidemia. Thus,
demonstrating potential effectiveness of CQAs in those subjects at high CVD risk.
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Regarding sex differences, the eight-week supplementation of a CQA-rich artichoke leaf
extract significantly increased HDL-C in primary mild hypercholesterolemic study participants
(0.207 mmol/L) [54]. However, when sex groups were compared, an increase in HDL was only
significant for males and reductions in TG were only seen for women. However, when groups were
further stratified by median HDL level, there was a significant increase in HDL in women who had
≤median HDL. The impact of sex was also considered in a study enrolling 80 patients with MetS and
screened for polymorphisms of cholesteryl ester transfer protein (CETP), which is directly related
to MetS risk [58]. Although there was no interaction in the whole population between CETP gene
mutation and response to 12-week ALE supplementation (~22 mg CQAs), the subgroup analysis
revealed that only men with CETP gene mutation had significantly lower LDL-C levels after 12-week
supplementation, compared to placebo.
The inter-individual variability associated with the dietary pattern was taken into account by
Ioakeimidis and colleagues [49] in an acute study focusing on habitual coffee consumption. Results
revealed positive effects of both caffeinated and decaffeinated coffee consumption (79 mg CQAs each)
on markers of arterial stiffness in non-habitual compared to habitual coffee consumers (maximal
differences of changes in responses by 4.5%). As some markers, not subject of this systematic
review (i.e., pulse wave velocity and augmentation index), increased only after decaffeinated coffee
consumption in non-habitual consumers, authors hypothesized that the effect was related to compounds
other than caffeine and supported the potential role of coffee habituation as determinant of its effect on
vascular function.
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Table 3. Main findings of studies investigating the effect of HCA-rich foods on cardiometabolic markers and considering determinants of inter-individual variability.
Reference Determinant of Inter-Individual Variability Main Findings
Acute studies
Ioakeimidis et al. 2018 [49] Dietary pattern (habitual and non habitulcoffee consumers) = BP between habitual and non-habitual consumers
Iwai et al. 2013 [35] Pathophysiological status (high glycemic response vs.total mean glycemic response) ↓glucose after both 100 mg 300 mg EDGCB in high glycemic response group
Jokura et al. 2015 [46] Pathophysiological status (lower or higherinsulinogenic index)
↓blood glucose after CPE compared to the placebo in study participants with a
lower insulinogenic index
↑postprandial FMD after CPE compared to the placebo in study participants
with either lower or higher insulinogenic index
Chronic studies
Martínez-López et al. 2018 [28]
*
Pathophysiological status (normocholesterolemia vs.
hypercholesterolemia) ↓TC, LDL, TG only in HC
Sarriá et al. 2018 [26] * Pathophysiological status (normocholesterolemia vs.hypercholesterolemia)
↓SBP, DBP only in HC
↓HOMA-IR in both HC and NC separately
= glucose in either HC or NC separately
Rezazadeh et al. 2018 [58]
-Taq IB polymorphism in cholesteryl ester transfer
protein gene (B1B1 vs. B2 allel)
-Sex (men vs. women with the selected polymorphisms)
Similar changes in lipid profile among Taq IB genotype compared to placebo
↓LDL in men with B1B1 genotype after ALE
Rondanelli et al. 2013 [54] Sex (men vs. women)Stratified by median HDL
↑HDL in men only
↓LDL, TC in men and women
↓ TG in women only
↑ HDL in men in both strata
↑HDL in women in ≤median HDL strata
Legend: ALE: Artichoke leaf extract; CPE: Coffee polyphenol extract; DBP: Diastolic blood pressure; EDGCB: Decaffeinated green coffee beans extract; FMC: Flow mediated dilation; HC:
Hypercholesterolemic; HDL: High density lipoprotein; HOMA: Homeostatic model assessment; IFG: Impaired fasting glucose; IGT: Impaired glucose tolerance; IR: Insulin resistance; LDL:
Low density lipoprotein; NC: Normocholesterolemic; PP: Pulse pressure; TC: Total cholesterol; SBP: Systolic blood pressure; TG: Triglycerides; =: No statistically significant effect; ↑:
Significant increase; ↓: Significant decrease. * These publications correspond to the same RCT.
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4. Discussion
There is a clear interest in the exploitation of phenolic-rich foods as potential modulators of markers
of CM health, and the present review aimed at summarizing the main findings from RCTs focused on
HCA-rich foods. The observed intervention effects had clinical relevance mostly in study participants
at high CVD risk. Conversely, many studies performed on self-reported healthy individuals failed to
find any effect of HCAs, increasing the heterogeneity of the results and making it difficult to draw any
clear conclusion.
In the present review, only seven studies out of the 45 included publications considered one or
more determinants of inter-individual variability in response to HCAs, while the remaining studies
did not stratify results based on these parameters. This hinders our understanding of the role played
by these determinants in the individual response to HCA-rich foods.
Despite limited, results from these seven studies suggest that some individual characteristics may
influence the beneficial effect of HCAs. Firstly, determinants of health or pathophysiological status,
like baseline cholesterol levels [26,28], insulinogenic index [46] or glycemic response [35] could play an
important role in the variation among study participants in the biological response to HCAs regarding
CM outcomes, being associated with an increased beneficial effect following HCA intake. This was not
only demonstrated in the stratified analyses conducted by Martinez-Lopez et al., Sarriá et al., Iwai et al.
and Jokura et al., [26,28,35,46] but also in the assessments conducted within this systematic review
for all outcomes in the chronic studies, which demonstrated that effectiveness of HCAs, regardless
of specific source, was greater in those at higher risk (i.e., greater baseline cholesterol, glycemic or
SBP). This supports previous studies that suggested that the pathophysiological status can lead to
inter-individual variation in response to polyphenols [74,75]. Some recent systematic reviews and
meta-analyses have also indicated that the health status or BMI may influence the impact of several
polyphenols (flavonols, flavan-3-ols, anthocyanins and ellagitannins) on blood lipid levels [18,19,24].
Regarding sex differences, the response to HCAs has been shown to be different between men
and women following artichoke leaf extract consumption [54]. So far, a sex effect in response to
plant-food bioactive compounds such as HCAs has been reported in very few studies [76], mainly
focusing on flavanol-rich products, with some but limited differences in the response between men
and women. However, results are often contrasting; for instance, a decreased augmentation index was
observed only in women after cocoa consumption for four weeks [77], while the antioxidant status was
improved mostly in men after a four-week consumption of ready-to-eat meals supplemented with
cocoa extract [78]. Again, TC and LDL were significantly reduced only in females after intervention
with flavanol-containing products [19]. Similarly to what happens for other individual characteristics,
the lack of differences in the response among men and women after consumption of HCAs could be
due to the lack of statistical power resulting from smaller sample sizes after the stratification process.
Genetic polymorphisms have also been shown to impact the effect of plant compounds from
different sources [79], since they are often present in genes encoding for enzymes involved in the
metabolism of these bioactives. Regarding coffee, mostly polymorphisms related to caffeine metabolism
have been investigated, above all the cytochrome P450 as CYP1A2 accounts for about 95% of caffeine
metabolism, with a high inter-individual variability in activity [80]. In the present review, only one
study investigating variation based on polymorphisms (in CETP Taq 1B) was included [58], suggesting
that genetic polymorphism may predict the lipid responsiveness to HCA intake.
An additional determinant, not explored in any of the studies included in the present review, may
likely be age, which is the strongest independent cardiovascular risk factor. Overall, the impact of age
on the response to the consumption of plant food bioactives has received very limited attention [17].
Differences due to age might depend on variability in absorption, distribution, metabolism and
excretion (ADME), as recently showed by Alkhaldy and colleagues, who found variation in the urinary
phenolic acid profile between younger and older adults after a polyphenol-rich meal [81].
The inter-individual variability in the biological response to the consumption of phenolic
compounds, such as HCAs, may be partially related to the inter-individual variation in the bioavailability
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and metabolism of these compounds [16]. Several human studies have demonstrated that the
plasma concentrations and the urinary excretion of phenolics or their derived metabolites can differ
markedly between individuals following a similar intake of plant food bioactives, due to variances
in their ADME [82,83]. Despite a small amount of some (poly)phenols being absorbed in the upper
gastrointestinal tract (and being subjected to glucuronidation, sulfation or methylation by the gut
epithelium and/or liver) most compounds reach the lower gastrointestinal tract unmodified, where
they undergo extensive metabolism [83]. Thus, a key role is played by the gut microbiota, which may
modify the structure of polyphenols, releasing these colonic catabolites into the portal vein towards the
liver, where they can: (i) Directly enter the bloodstream, (ii) undergo phase I and II metabolism and then
enter the bloodstream and (iii) undergo enterohepatic recirculation until complete detoxification [84].
This long and complex physiological mechanism and the influence of gut microbiota composition
form the pathway through which different types and levels of metabolites enter circulation where they
may have metabolic effects. This is supported by the work by Stalmach and colleagues who assessed
the metabolic fate of CGAs from coffee [85] and demonstrated that ~1 h after the consumption of instant
coffee, low nanomolar concentrations of CQA lactones and caffeic acid sulfates reached the plasma.
Although it has been hypothesized that quinic-HCA linkage is hydrolyzed with consequently few
HCA conjugates being absorbed [83], ~5 h after coffee consumption, gut-derived phase II metabolites
were detected in much higher concentrations in plasma showing high inter-individual differences.
Gut microbial esterases can rapidly hydrolyze the quinic-phenolic linkage and convert the HCA into
dihydroxy forms and further metabolism of these compounds by gut microbial strains leads to the
formation of smaller catabolites [83,86,87]. Thus, future studies assessing the profile of phenolic
metabolites in circulation in addition to variations in gut microbiota composition would be highly
valuable in understanding the potential effectiveness of HCAs. Among the 44 included RCTs, only the
one by Mills and colleagues [25] considered circulating metabolites and found that FMD responses to
coffee intake were closely paralleled by the appearance of CGA metabolites in plasma.
In the framework of an intervention study, these aspects are further complicated by considering
that the same colonic metabolites can be produced after the consumption of different classes of
phenolic-rich foods. For example, in vitro and in vivo studies have shown that after berry, coffee,
cocoa or orange consumption, the phenolic metabolic degradation pathways reach some common
intermediates, most of them HCA or hydroxybenzoic acid derivatives, which can be further metabolized
into smaller compounds [83,88,89]. To avoid this further confounding factor, some researchers have
applied different strategies, such as: (i) Asking participants to maintain their usual diet; (ii) telling
participant to refrain from consuming selected foods, rich in (poly) phenol compounds similar to those
of the intervention and (iii) advising a low-/free-polyphenol diet in the day(s) prior to sample collection.
The limitations of the present systematic review include that there were relatively few studies
(n = 7), which explored potential determinants of inter-individual variability, thus there may be other
variables that may influence the effectiveness of HCAs on CM biomarkers. Additionally, of those
included studies, there was a wide range of methods by which HCAs were delivered, as well as ranges
of doses, including those coming from coffee (plain coffee and green coffee extracts consumed in a
variety of forms (soups, capsules, in a test beverage and in fruit juice)) and foods (purple potatoes, whole
grain biscuits and artichoke leaf extract), which may also influence the effect of HCAs. Furthermore,
some studies controlled for caffeine whereas others did not, and considering the majority of studies
focused on coffee, this also potentially confounds the ability to determine the effect of HCAs. In
addition, further efforts should be paid on the contribution of other phytochemicals to the observed
effects when dealing with food products rich in different bioactive compounds. A good example may
be coffee, where the presence and amount of some compounds like caffeine, trigonelline and HHQ may
affect the response to the intervention [8,38,64]. Lastly, it may be a limitation that only two databases
were used for conducting the search and thus may not have captured all existing studies on HCAs,
however manual searches of the reference lists of all included studies, supplemented the search to
minimize this potential issue.
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Overall, the studies were characterized by a high variability in study design and methods
of outcome assessment and, consequently, comparisons among findings of the different studies
challenging. In addition to the health status of the volunteers, major sources of variability include
the type of HCA-based product (e.g., pure compounds, foods and beverages) and the dose of HCAs,
which broadly ranged in both acute and chronic studies. It is worth noting that, even when the same
HCA-food source was used as test food (e.g., coffee) in different investigations, a high variability
in terms of phenolic content was observed. This further supports the importance of an in-depth
characterization of the phenolic profile of the test items and, when possible, taking into account the
actual phenolic amount provided by a single serving [90,91]. In addition to the above-mentioned
sources of variability, studies often lacked in information on determinants that are known to influence
CM biomarkers, such as BMI, age, sex, smoking habits, dietary patterns, physical activity levels
or specific polymorphisms. Improvements in reporting possible determinants of inter-individual
variability are needed to make secondary data analysis feasible [92].
5. Conclusions
The present review summarized the main findings of RCTs investigating the effect of HCA-rich
foods on CM health, with a particular focus on the determinants of inter-individual variability such as
pathophysiological status, sex or specific polymorphisms. Generally, there are limited studies that
conduct stratified analyses to explore factors leading to inter-individual variation in the effect of HCAs
to modulate CM outcomes, thus limiting the ability to conclude which factors may modulate the
effectiveness of HCAs. However, the present systematic review demonstrates that overall, HCAs have
greater effectiveness, regardless of the variation in the source of HCAs, in those subjects with greater
baseline levels of cardiovascular risk factors such as cholesterol, BP and glycaemia. Further high
quality, well powered RCTs with a low risk of bias should be performed, reporting all characteristics
that may influence the individual response to these compounds, including but not limited to sex, age,
BMI, pathophysiological status, presence of genetic polymorphisms, smoking habits, physical activity
level and dietary patterns.
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